# Jeff Gershenwald

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9345304/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 358 papers | 53,558 citations | 3325 91 h-index | 1413 221 g-index |
| 374 all docs | 374 docs citations | 374 times ranked | 45564 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Final Version of 2009 AJCC Melanoma Staging and Classification. Journal of Clinical Oncology, 2009, 27, 6199-6206. | 0.8 | 4,126 |
| 2 | The Eighth Edition <scp>AJCC</scp> Cancer Staging Manual: Continuing to build a bridge from a populationâ€based to a more â€œpersonalizedâ€•approach to cancer staging. Ca-A Cancer Journal for Clinicians, 2017, 67, 93-99. | 157.7 | 3,940 |
| 3 | Gut microbiome modulates response to antiâ€“PD-1 immunotherapy in melanoma patients. Science, 2018, 359, 97-103. | 6.0 | 3,126 |
| 4 | Genomic Classification of Cutaneous Melanoma. Cell, 2015, 161, 1681-1696. | 13.5 | 2,562 |
| 5 | Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. Journal of Clinical Oncology, 2001, 19, 3635-3648. | 0.8 | 2,462 |
| 6 | Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System. Journal of Clinical Oncology, 2001, 19, 3622-3634. | 0.8 | 2,394 |
| 7 | A Landscape of Driver Mutations in Melanoma. Cell, 2012, 150, 251-263. | 13.5 | 2,247 |
| 8 | Melanoma staging: Evidenceâ€based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Ca-A Cancer Journal for Clinicians, 2017, 67, 472-492. | 157.7 | 1,662 |
| 9 | B cells and tertiary lymphoid structures promote immunotherapy response. Nature, 2020, 577, 549-555. | 13.7 | 1,421 |
| 10 | Multi-Institutional Melanoma Lymphatic Mapping Experience: The Prognostic Value of Sentinel Lymph Node Status in 612 Stage I or II Melanoma Patients. Journal of Clinical Oncology, 1999, 17, 976-976. | 0.8 | 1,166 |
| 11 | Loss of PTEN Promotes Resistance to T Cellâ€“Mediated Immunotherapy. Cancer Discovery, 2016, 6, 202-216. | 7.7 | 1,158 |
| 12 | Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. New England Journal of Medicine, 2017, 376, 2211-2222. | 13.9 | 1,087 |
| 13 | Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discovery, 2016, 6, 827-837. | 7.7 | 785 |
| 14 | Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Science Translational Medicine, 2017, 9, . | 5.8 | 689 |
| 15 | Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell, 2017, 32, 204-220.e15. | 7.7 | 642 |
| 16 | Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nature Medicine, 2018, 24, 1649-1654. | 15.2 | 592 |
| 17 | NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer, 2012, 118, 4014-4023. | 2.0 | 589 |
| 18 | Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma.. Journal of Clinical Oncology, 1998, 16, 2253-2260. | 0.8 | 546 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging system. Journal of the American Academy of Dermatology, 2010, 63, 751-761. | 0.6 | 504 |
| 20 | Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncology, The, 2018, 19, 310-322. | 5.1 | 486 |
| 21 | Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nature Genetics, 2011, 43, 442-446. | 9.4 | 449 |
| 22 | Melanoma. Nature Reviews Disease Primers, 2015, 1, 15003. | 18.1 | 417 |
| 23 | Guidelines of care for the management of primary cutaneous melanoma. Journal of the American Academy of Dermatology, 2019, 80, 208-250. | 0.6 | 400 |
| 24 | A new American Joint Committee on Cancer staging system for cutaneous melanoma. , 2000, 88, 1484-1491. | | 389 |
| 25 | Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus Macrometastases. Journal of Clinical Oncology, 2010, 28, 2452-2459. | 0.8 | 374 |
| 26 | Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science, 2021, 374, 1632-1640. | 6.0 | 369 |
| 27 | Activation of Stat3 in Human Melanoma Promotes Brain Metastasis. Cancer Research, 2006, 66, 3188-3196. | 0.4 | 366 |
| 28 | Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients. Clinical Cancer Research, 2012, 18, 6758-6770. | 3.2 | 345 |
| 29 | Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. Annals of Surgical Oncology, 2018, 25, 2105-2110. | 0.7 | 338 |
| 30 | An Evidence-based Staging System for Cutaneous Melanoma. Ca-A Cancer Journal for Clinicians, 2004, 54, 131-149. | 157.7 | 322 |
| 31 | Prognostic Significance of Mitotic Rate in Localized Primary Cutaneous Melanoma: An Analysis of Patients in the Multi-Institutional American Joint Committee on Cancer Melanoma Staging Database. Journal of Clinical Oncology, 2011, 29, 2199-2205. | 0.8 | 313 |
| 32 | Contemporary Diagnostic Imaging Modalities for the Staging and Surveillance of Melanoma Patients: a Meta-analysis. Journal of the National Cancer Institute, 2011, 103, 129-142. | 3.0 | 297 |
| 33 | Ethnic Differences Among Patients With Cutaneous Melanoma. Archives of Internal Medicine, 2006, 166, 1907. | 4.3 | 292 |
| 34 | Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. American Journal of Pathology, 1997, 151, 1105-13. | 1.9 | 292 |
| 35 | American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. Ca-A Cancer Journal for Clinicians, 2016, 66, 370-374. | 157.7 | 280 |
| 36 | The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Review of Anticancer Therapy, 2018, 18, 775-784. | 1.1 | 268 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Sentinel Lymph Node Biopsy for Melanoma: How Many Radioactive Nodes Should be Removed?. Annals of Surgical Oncology, 2001, 8, 192-197. | 0.7 | 258 |
| 38 | A novel AKT3 mutation in melanoma tumours and cell lines. British Journal of Cancer, 2008, 99, 1265-1268. | 2.9 | 237 |
| 39 | Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma. Clinical Cancer Research, 2011, 17, 229-235. | 3.2 | 237 |
| 40 | Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncology, The, 2018, 19, 181-193. | 5.1 | 233 |
| 41 | Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discovery, 2019, 9, 628-645. | 7.7 | 231 |
| 42 | Role for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Thick (?4 mm) Primary Melanoma. Annals of Surgical Oncology, 2000, 7, 160-165. | 0.7 | 225 |
| 43 | Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clinical Cancer Research, 2009, 15, 7538-7546. | 3.2 | 221 |
| 44 | Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nature Medicine, 2021, 27, 1432-1441. | 15.2 | 216 |
| 45 | Sentinel Lymph Node Biopsy for Melanoma: Controversy Despite Widespread Agreement. Journal of Clinical Oncology, 2001, 19, 2851-2855. | 0.8 | 211 |
| 46 | Lessons learned from the Sunbelt Melanoma Trial. Journal of Surgical Oncology, 2004, 86, 212-223. | 0.8 | 209 |
| 47 | Phase II trial of imatinib mesylate in patients with metastatic melanoma. British Journal of Cancer, 2008, 99, 734-740. | 2.9 | 205 |
| 48 | Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nature Cell Biology, 2015, 17, 311-321. | 4.6 | 205 |
| 49 | Interleukin 1 receptor blockade attenuates the host inflammatory response.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 4966-4970. | 3.3 | 197 |
| 50 | Surgical margins and prognostic factors in patients with thick (>4 mm) primary melanoma. Annals of Surgical Oncology, 1998, 5, 322-328. | 0.7 | 192 |
| 51 | Predictors and Natural History of In-Transit Melanoma After Sentinel Lymphadenectomy. Annals of Surgical Oncology, 2005, 12, 587-596. | 0.7 | 192 |
| 52 | Microscopic Tumor Burden in Sentinel Lymph Nodes Predicts Synchronous Nonsentinel Lymph Node Involvement in Patients With Melanoma. Journal of Clinical Oncology, 2008, 26, 4296-4303. | 0.8 | 190 |
| 53 | Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery, 1998, 124, 203-210. | 1.0 | 188 |
| 54 | Genome-wide association study identifies novel loci predisposing to cutaneous melanomaâ€. Human Molecular Genetics, 2011, 20, 5012-5023. | 1.4 | 187 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Revised American Joint Committee on Cancer Staging Criteria Accurately Predict Sentinel Lymph Node Positivity in Clinically Node-Negative Melanoma Patients. Annals of Surgical Oncology, 2003, 10, 569-574. | 0.7 | 186 |
| 56 | Invasive Squamous Cell Carcinoma of the Skin: Defining a High-Risk Group. Annals of Surgical Oncology, 2006, 13, 902-909. | 0.7 | 173 |
| 57 | Title is missing!. , 2017, , . | | 171 |
| 58 | Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base. Journal of the National Cancer Institute, 2016, 108, djw042. | 3.0 | 170 |
| 59 | Melanoma Patients with Positive Sentinel Nodes Who Did Not Undergo Completion Lymphadenectomy: A Multi-Institutional Study. Annals of Surgical Oncology, 2006, 13, 809-816. | 0.7 | 161 |
| 60 | Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncology, The, 2019, 20, e378-e389. | 5.1 | 155 |
| 61 | Repair of UV Light-Induced DNA Damage and Risk of Cutaneous Malignant Melanoma. Journal of the National Cancer Institute, 2003, 95, 308-315. | 3.0 | 149 |
| 62 | Staging and Prognosis of Cutaneous Melanoma. Surgical Oncology Clinics of North America, 2011, 20, 1-17. | 0.6 | 148 |
| 63 | Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 13481-13486. | 3.3 | 147 |
| 64 | Age as a Prognostic Factor in Patients with Localized Melanoma and Regional Metastases. Annals of Surgical Oncology, 2013, 20, 3961-3968. | 0.7 | 146 |
| 65 | Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with BRAFV600 Mutations. Clinical Cancer Research, 2014, 20, 5527-5536. | 3.2 | 145 |
| 66 | Loss of AP-2 Results in Up-regulation ofMCAM/MUC18 and an Increase in Tumor Growth and Metastasis of Human Melanoma Cells. Journal of Biological Chemistry, 1998, 273, 16501-16508. | 1.6 | 141 |
| 67 | Sphincter-Sparing Local Excision and Adjuvant Radiation for Anal-Rectal Melanoma. Journal of Clinical Oncology, 2002, 20, 4555-4558. | 0.8 | 140 |
| 68 | State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now. Ca-A Cancer Journal for Clinicians, 2016, 66, 460-480. | 157.7 | 140 |
| 69 | Prospective Assessment of Postoperative Complications and Associated Costs Following Inguinal Lymph Node Dissection (ILND) in Melanoma Patients. Annals of Surgical Oncology, 2010, 17, 2764-2772. | 0.7 | 139 |
| 70 | Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. Journal of Investigative Dermatology, 2015, 135, 508-515. | 0.3 | 138 |
| 71 | Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Annals of Oncology, 2018, 29, 1861-1868. | 0.6 | 135 |
| 72 | Hepatic Resection for Metastatic Melanoma: Distinct Patterns of Recurrence and Prognosis for Ocular Versus Cutaneous Disease. Annals of Surgical Oncology, 2006, 13, 712-720. | 0.7 | 133 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nature Genetics, 2011, 43, 1119-1126. | 9.4 | 133 |
| 74 | Sentinel node biopsy and standard of care for melanoma. Journal of the American Academy of Dermatology, 2009, 60, 872-875. | 0.6 | 132 |
| 75 | Sentinel-Lymph-Node Biopsy for Cutaneous Melanoma. New England Journal of Medicine, 2011, 364, 1738-1745. | 13.9 | 127 |
| 76 | Age as a Predictor of Sentinel Node Metastasis among Patients with Localized Melanoma: An Inverse Correlation of Melanoma Mortality and Incidence of Sentinel Node Metastasis Among Young and Old Patients. Annals of Surgical Oncology, 2014, 21, 1075-1081. | 0.7 | 123 |
| 77 | Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. Cancer, 2006, 106, 900-906. | 2.0 | 122 |
| 78 | Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. Npj Genomic Medicine, 2017, 2, . | 1.7 | 120 |
| 79 | The Risk of In-Transit Melanoma Metastasis Depends on Tumor Biology and Not the Surgical Approach to Regional Lymph Nodes. Journal of Clinical Oncology, 2005, 23, 4588-4590. | 0.8 | 114 |
| 80 | Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer, 2006, 106, 2012-2020. | 2.0 | 113 |
| 81 | Update on the melanoma staging system: The importance of sentinel node staging and primary tumor mitotic rate. Journal of Surgical Oncology, 2011, 104, 379-385. | 0.8 | 112 |
| 82 | 2010 TNM Staging System for Cutaneous Melanomaâ€¦and Beyond. Annals of Surgical Oncology, 2010, 17, 1475-1477. | 0.7 | 111 |
| 83 | Adjuvant irradiation for axillary metastases from malignant melanoma. International Journal of Radiation Oncology Biology Physics, 2002, 52, 964-972. | 0.4 | 110 |
| 84 | Improved Staging of Node-Negative Patients With Intermediate to Thick Melanomas (>1 mm) With the Use of Lymphatic Mapping and Sentinel Lymph Node Biopsy. Annals of Surgical Oncology, 2001, 8, 766-770. | 0.7 | 109 |
| 85 | Relationships among primary tumor size, number ofÂinvolved nodes, and survival for 8044 cases ofÂMerkel cell carcinoma. Journal of the American Academy of Dermatology, 2014, 70, 637-643. | 0.6 | 108 |
| 86 | Structure function relationships in the lymphatic system and implications for cancer biology. Cancer and Metastasis Reviews, 2006, 25, 159-184. | 2.7 | 107 |
| 87 | Predicting Survival Outcome of Localized Melanoma: An Electronic Prediction Tool Based on the AJCC Melanoma Database. Annals of Surgical Oncology, 2010, 17, 2006-2014. | 0.7 | 106 |
| 88 | Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Medicine, 2016, 14, 168. | 2.3 | 106 |
| 89 | Role of Sentinel Lymph Node Biopsy in Patients with Thin Melanoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 308-317. | 2.3 | 105 |
| 90 | New TNM melanoma staging system: Linking biology and natural history to clinical outcomes. Journal of Surgical Oncology, 2003, 21, 43-52. | 1.4 | 103 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Contralateral prophylactic mastectomy. Cancer, 2004, 101, 1977-1986. | 2.0 | 102 |
| 92 | Impact of Sentinel Node Status and Other Risk Factors on the Clinical Outcome of Head and Neck Melanoma Patients. JAMA Otolaryngology, 2006, 132, 370. | 1.5 | 93 |
| 93 | Factors Associated with False-Negative Sentinel Lymph Node Biopsy in Melanoma Patients. Annals of Surgical Oncology, 2010, 17, 709-717. | 0.7 | 93 |
| 94 | Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. Cancer, 2006, 107, 2647-2652. | 2.0 | 92 |
| 95 | CpG island methylation profiling in human melanoma cell lines. Melanoma Research, 2009, 19, 146-155. | 0.6 | 91 |
| 96 | Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clinical Cancer Research, 2018, 24, 4416-4428. | 3.2 | 89 |
| 97 | Implications of lymphatic drainage to unusual sentinel lymph node sites in patients with primary cutaneous melanoma. Cancer, 2002, 95, 354-360. | 2.0 | 87 |
| 98 | Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer, 2013, 119, 3821-3829. | 2.0 | 87 |
| 99 | Population-Based Assessment of Surgical Treatment Trends for Patients With Melanoma in the Era of Sentinel Lymph Node Biopsy. Journal of Clinical Oncology, 2005, 23, 6054-6062. | 0.8 | 86 |
| 100 | Utility of Computed Tomography and Magnetic Resonance Imaging Staging Before Completion Lymphadenectomy in Patients With Sentinel Lymph Nodeâ€“Positive Melanoma. Journal of Clinical Oncology, 2006, 24, 2858-2865. | 0.8 | 86 |
| 101 | Galectin-3 Expression Is Associated with Tumor Progression and Pattern of Sun Exposure in Melanoma. Clinical Cancer Research, 2006, 12, 6709-6715. | 3.2 | 84 |
| 102 | Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram. Journal of Clinical Oncology, 2020, 38, 2719-2727. | 0.8 | 84 |
| 103 | Title is missing!. , 2017, , . | | 82 |
| 104 | Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell and Melanoma Research, 2015, 28, 135-147. | 1.5 | 81 |
| 105 | Significance of Multiple Nodal Basin Drainage in Truncal Melanoma Patients Undergoing Sentinel Lymph Node Biopsy. Annals of Surgical Oncology, 2000, 7, 256-261. | 0.7 | 80 |
| 106 | Polymorphisms in the DNA Repair Genes XPC, XPD, and XPG and Risk of Cutaneous Melanoma: a Case-Control Analysis. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 2526-2532. | 1.1 | 80 |
| 107 | Immunohistochemical detection of lymphovascular invasion with D2â€40 in melanoma correlates with sentinel lymph node status, metastasis and survival. Journal of Cutaneous Pathology, 2009, 36, 1157-1163. | 0.7 | 80 |
| 108 | Combined-modality therapy for patients with regional nodal metastases from melanoma. International Journal of Radiation Oncology Biology Physics, 2006, 64, 106-113. | 0.4 | 78 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Factors Predictive of the Status of Sentinel Lymph Nodes in Melanoma Patients from a Large Multicenter Database. Annals of Surgical Oncology, 2011, 18, 3593-3600. | 0.7 | 78 |
| 110 | Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma. Carcinogenesis, 2006, 27, 1894-1901. | 1.3 | 77 |
| 111 | Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer Therapyâ€Melanoma questionnaire. Cancer, 2008, 112, 2249-2257. | 2.0 | 77 |
| 112 | The state of melanoma: challenges and opportunities. Pigment Cell and Melanoma Research, 2016, 29, 404-416. | 1.5 | 77 |
| 113 | Conditional survival estimates improve over time for patients with advanced melanoma. Cancer, 2010, 116, 2234-2241. | 2.0 | 74 |
| 114 | Outcomes in Pediatric Melanoma. Annals of Surgery, 2011, 253, 1211-1215. | 2.1 | 74 |
| 115 | Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo. Oncogene, 2001, 20, 3363-3375. | 2.6 | 71 |
| 116 | Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer, 2004, 100, 383-389. | 2.0 | 71 |
| 117 | Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18637-18642. | 3.3 | 71 |
| 118 | C-Reactive Protein As a Marker of Melanoma Progression. Journal of Clinical Oncology, 2015, 33, 1389-1396. | 0.8 | 71 |
| 119 | Melanoma adrenal metastasis: natural history and surgical management. American Journal of Surgery, 2008, 195, 363-369. | 0.9 | 69 |
| 120 | Automated Quantitative Analysis of Activator Protein-2Î± Subcellular Expression in Melanoma Tissue Microarrays Correlates with Survival Prediction. Cancer Research, 2005, 65, 11185-11192. | 0.4 | 68 |
| 121 | A Subset of Host B Lymphocytes Controls Melanoma Metastasis through a Melanoma Cell Adhesion Molecule/MUC18-Dependent Interaction: Evidence from Mice and Humans. Cancer Research, 2008, 68, 8419-8428. | 0.4 | 68 |
| 122 | A Critical Assessment of Adjuvant Radiotherapy for Inguinal Lymph Node Metastases from Melanoma. Annals of Surgical Oncology, 2004, 11, 1079-1084. | 0.7 | 66 |
| 123 | Multimethod imaging, staging, and spectrum of manifestations of metastatic melanoma. Clinical Radiology, 2011, 66, 224-236. | 0.5 | 66 |
| 124 | Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy. Journal of Clinical Oncology, 2016, 34, 1079-1086. | 0.8 | 66 |
| 125 | Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. Journal of Clinical Oncology, 2016, 34, 1741-1747. | 0.8 | 64 |
| 126 | Stemming the Rising Incidence of Melanoma: Calling Prevention to Action. Journal of the National Cancer Institute, 2016, 108, . | 3.0 | 61 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Melanoma pathology reporting and staging. Modern Pathology, 2020, 33, 15-24. | 2.9 | 61 |
| 128 | Lymph node ratio predicts diseaseâ€specific survival in melanoma patients. Cancer, 2009, 115, 2505-2513. | 2.0 | 60 |
| 129 | A highly recurrent RPS27 5'UTR mutation in melanoma. Oncotarget, 2014, 5, 2912-2917. | 0.8 | 60 |
| 130 | Evidenceâ€based treatment of earlyâ€stage melanoma. Journal of Surgical Oncology, 2011, 104, 341-353. | 0.8 | 59 |
| 131 | KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncology, 2020, 16, 4429-4438. | 1.1 | 59 |
| 132 | Prognostic Gene Expression Profiling in Cutaneous Melanoma. JAMA Dermatology, 2020, 156, 1004. | 2.0 | 59 |
| 133 | Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in nonâ€Hispanic whites in Texas: A caseâ€“control study. International Journal of Cancer, 2008, 122, 2077-2084. | 2.3 | 58 |
| 134 | Pelvic Lymph Node Dissection Is Beneficial in Subsets of Patients with Node-positive Melanoma. Annals of Surgical Oncology, 2007, 14, 2867-2875. | 0.7 | 56 |
| 135 | Fibrin sealant does not decrease seroma output or time to drain removal following inguino-femoral lymph node dissection in melanoma patients: A randomized controlled trial (NCT00506311). World Journal of Surgical Oncology, 2008, 6, 63. | 0.8 | 55 |
| 136 | Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. OncoImmunology, 2016, 5, e1136044. | 2.1 | 55 |
| 137 | Tolerance to Endotoxin Prevents Mortality in Infected Thermal Injury: Association with Attenuated Cytokine Responses. Journal of Infectious Diseases, 1992, 165, 859-864. | 1.9 | 54 |
| 138 | Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature, 2022, 606, 797-803. | 13.7 | 54 |
| 139 | CANCER: Targeting Lymphatic Metastasis. Science, 2002, 296, 1811-1812. | 6.0 | 53 |
| 140 | The State of Melanoma: Emergent Challenges and Opportunities. Clinical Cancer Research, 2021, 27, 2678-2697. | 3.2 | 53 |
| 141 | In Vitro Sensitivity to Ultraviolet B Light and Skin Cancer Risk: A Caseâ€“Control Analysis. Journal of the National Cancer Institute, 2005, 97, 1822-1831. | 3.0 | 52 |
| 142 | Mutational and Functional Analysis Reveals ADAMTS18 Metalloproteinase as a Novel Driver in Melanoma. Molecular Cancer Research, 2010, 8, 1513-1525. | 1.5 | 52 |
| 143 | How many lymph nodes are enough during sentinel lymphadenectomy for primary melanoma?. Surgery, 2000, 128, 306-311. | 1.0 | 51 |
| 144 | Genetic Variants of the Vitamin D Receptor Gene Alter Risk of Cutaneous Melanoma. Journal of Investigative Dermatology, 2007, 127, 276-280. | 0.3 | 50 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Regional Nodal basin control is not compromised by previous sentinel lymph node biopsy in patients with melanoma. Annals of Surgical Oncology, 2000, 7, 226-231. | 0.7 | 49 |
| 146 | Genetic variants and haplotypes of thecaspase-8andcaspase-10genes contribute to susceptibility to cutaneous melanoma. Human Mutation, 2008, 29, 1443-1451. | 1.1 | 49 |
| 147 | Feasibility of Adjuvant Hepatic Arterial Infusion of Chemotherapy After Radiofrequency Ablation With or Without Resection in Patients With Hepatic Metastases From Colorectal Cancer. Annals of Surgical Oncology, 2003, 10, 348-354. | 0.7 | 48 |
| 148 | Impact of Clinical and Pathologic Features on Tumor-Infiltrating Lymphocyte Expansion from Surgically Excised Melanoma Metastases for Adoptive T-cell Therapy. Clinical Cancer Research, 2011, 17, 4882-4891. | 3.2 | 48 |
| 149 | Variability in melanoma post-treatment surveillance practices by country and physician specialty. Melanoma Research, 2012, 22, 376-385. | 0.6 | 48 |
| 150 | Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases. Clinical Cancer Research, 2017, 23, 2093-2104. | 3.2 | 48 |
| 151 | Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma. Melanoma Research, 2013, 23, 290-297. | 0.6 | 47 |
| 152 | Virtual Interviews for Surgical Training Program Applicants During COVID-19: Lessons Learned and Recommendations. Annals of Surgery, 2020, 272, e144-e147. | 2.1 | 47 |
| 153 | Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47). Clinical Cancer Research, 2013, 19, 3611-3620. | 3.2 | 46 |
| 154 | Is Surveillance Imaging Effective for Detecting Surgically Treatable Recurrences in Patients With Melanoma? A Comparative Analysis of Stage-Specific Surveillance Strategies. Annals of Surgery, 2014, 259, 1215-1222. | 2.1 | 46 |
| 155 | p53 Codon 72 Arg Homozygotes Are Associated with an Increased Risk of Cutaneous Melanoma. Journal of Investigative Dermatology, 2003, 121, 1510-1514. | 0.3 | 45 |
| 156 | Radiation Therapy Field Extent for Adjuvant Treatment of Axillary Metastases From Malignant Melanoma. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1376-1382. | 0.4 | 45 |
| 157 | Clinical impact of ulceration width, lymphovascular invasion, microscopic satellitosis, perineural invasion, and mitotic rate in patients undergoing sentinel lymph node biopsy for cutaneous melanoma: a retrospective observational study at a comprehensive cancer center. Cancer Medicine, 2018, 7, 583-593. | 1.3 | 45 |
| 158 | Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenetics and Genomics, 2006, 16, 253-263. | 0.7 | 44 |
| 159 | Constitutive Expression of the Î±4 Integrin Correlates with Tumorigenicity and Lymph Node Metastasis of the B16 Murine Melanoma. Neoplasia, 2010, 12, 173-182. | 2.3 | 44 |
| 160 | Mapping FACT-Melanoma Quality-of-Life Scores to EQ-5D Health Utility Weights. Value in Health, 2011, 14, 900-906. | 0.1 | 44 |
| 161 | Critical Assessment of Clinical Prognostic Tools in Melanoma. Annals of Surgical Oncology, 2016, 23, 2753-2761. | 0.7 | 44 |
| 162 | Quantitative Analysis of Melanocytic Tissue Array Reveals Inverse Correlation between Activator Protein-2Î± and Protease-Activated Receptor-1 Expression during Melanoma Progression. Journal of Investigative Dermatology, 2007, 127, 387-393. | 0.3 | 43 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Polymorphisms of Nucleotide Excision Repair Genes Predict Melanoma Survival. Journal of Investigative Dermatology, 2013, 133, 1813-1821. | 0.3 | 43 |
| 164 | Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Human Pathology, 2015, 46, 1101-1110. | 1.1 | 43 |
| 165 | How Should We View the Results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)?. Annals of Surgical Oncology, 2008, 15, 670-673. | 0.7 | 42 |
| 166 | FOXD3 Regulates VISTA Expression in Melanoma. Cell Reports, 2020, 30, 510-524.e6. | 2.9 | 42 |
| 167 | Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. Clinical Cancer Research, 2020, 26, 1886-1895. | 3.2 | 42 |
| 168 | Title is missing!. , 2017, , . | | 41 |
| 169 | Imaging Studies in Patients with Melanoma. Surgical Oncology Clinics of North America, 2007, 16, 403-430. | 0.6 | 40 |
| 170 | Clinical Value of the Sentinel-Node Biopsy in Primary Cutaneous Melanoma. New England Journal of Medicine, 2014, 370, 663-664. | 13.9 | 40 |
| 171 | Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes. Journal of Investigative Dermatology, 2017, 137, 1792-1795. | 0.3 | 40 |
| 172 | Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma. Clinical Cancer Research, 2016, 22, 3016-3024. | 3.2 | 39 |
| 173 | Cutaneous melanoma: A model to study cancer metastasis. Journal of Surgical Oncology, 2011, 103, 538-549. | 0.8 | 38 |
| 174 | Elevated Serum Leptin Levels are Associated With an Increased Risk of Sentinel Lymph Node Metastasis in Cutaneous Melanoma. Medicine (United States), 2016, 95, e3073. | 0.4 | 38 |
| 175 | A randomized phase III trial of biochemotherapy versus interferon-Î±-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Research, 2009, 19, 42-49. | 0.6 | 37 |
| 176 | The Challenge of Defining Guidelines for Sentinel Lymph Node Biopsy in Patients with Thin Primary Cutaneous Melanomas. Annals of Surgical Oncology, 2012, 19, 3301-3303. | 0.7 | 36 |
| 177 | Clinicopathological features and clinical outcomes associated with TP53 and BRAF<sup>N</sup><sup>onâ€</sup><sup>V</sup><sup>600</sup> mutations in cutaneous melanoma patients. Cancer, 2017, 123, 1372-1381. | 2.0 | 36 |
| 178 | Human Melanoma Cytolysis by Combined Inhibition of Mammalian Target of Rapamycin and Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor-2. Cancer Research, 2008, 68, 4392-4397. | 0.4 | 35 |
| 179 | Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 Centers. Journal of the National Cancer Institute, 2019, 111, 1314-1322. | 3.0 | 35 |
| 180 | CLASSIFICATION AND STAGING OF MELANOMA. Hematology/Oncology Clinics of North America, 1998, 12, 737-765. | 0.9 | 34 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Lifestyle Modifications and Policy Implications for Primary and Secondary Cancer Prevention: Diet, Exercise, Sun Safety, and Alcohol Reduction. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 88-100. | 1.8 | 34 |
| 182 | Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery, 1998, 124, 203-10. | 1.0 | 34 |
| 183 | Lymphangiogenesis and hemangiogenesis: Potential targets for therapy. Journal of Surgical Oncology, 2011, 103, 489-500. | 0.8 | 33 |
| 184 | Synchronous elective contralateral mastectomy and immediate bilateral breast reconstruction in women with early-stage breast cancer. Annals of Surgical Oncology, 1998, 5, 529-538. | 0.7 | 32 |
| 185 | Intraoperative Frozen-Section Evaluation Can Reduce Accuracy of Pathologic Assessment of Sentinel Nodes in Melanoma Patients. Journal of the American College of Surgeons, 2005, 201, 821-823. | 0.2 | 32 |
| 186 | Lysophosphatidic Acid Induces Lymphangiogenesis and IL-8 Production in Vitro in Human Lymphatic Endothelial Cells. American Journal of Pathology, 2012, 180, 2170-2181. | 1.9 | 32 |
| 187 | A Novel and Accurate Computer Model of Melanoma Prognosis for Patients Staged by Sentinel Lymph Node Biopsy: Comparison with the American Joint Committee on Cancer Model. Journal of the American College of Surgeons, 2012, 214, 608-617. | 0.2 | 31 |
| 188 | Is surviving enough? Coping and impact on activities of daily living among melanoma patients with lymphoedema. European Journal of Cancer Care, 2015, 24, 724-733. | 0.7 | 31 |
| 189 | Principles of Melanoma Staging. Cancer Treatment and Research, 2016, 167, 131-148. | 0.2 | 29 |
| 190 | Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer, 2019, 125, 18-44. | 2.0 | 29 |
| 191 | Significance of Plasma Cytokine Levels in Melanoma Patients With Histologically Negative Sentinel Lymph Nodes. Annals of Surgical Oncology, 2001, 8, 116-122. | 0.7 | 28 |
| 192 | Conditional Survival Estimates Improve Over 5 Years for Melanoma Survivors with Node-Positive Disease. Annals of Surgical Oncology, 2010, 17, 2015-2023. | 0.7 | 28 |
| 193 | Sentinel Lymph Node Biopsy in Melanoma. Cancer Journal (Sudbury, Mass ), 2012, 18, 185-191. | 1.0 | 28 |
| 194 | Randomized Controlled Trial of a Sun Protection Intervention for Children of Melanoma Survivors. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1813-1824. | 1.1 | 28 |
| 195 | Targeting Receptor Tyrosine Kinase on Lymphatic Endothelial Cells for the Therapy of Colon Cancer Lymph Node Metastasis. Neoplasia, 2006, 8, 747-757. | 2.3 | 27 |
| 196 | Adverse events associated with the intraoperative injection of isosulfan blue. Journal of Clinical Anesthesia, 2004, 16, 332-341. | 0.7 | 26 |
| 197 | The new melanoma staging system. Seminars in Cutaneous Medicine and Surgery, 2003, 22, 42-54. | 1.6 | 25 |
| 198 | Epidermal hyperplasia overlying human melanoma correlates with tumour depth and angiogenesis. Melanoma Research, 2003, 13, 379-387. | 0.6 | 25 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Cost Effectiveness of Adjuvant Interferon in Node-Positive Melanoma. Journal of Clinical Oncology, 2007, 25, 2442-2448. | 0.8 | 25 |
| 200 | Polymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, Contribute to Risk of Cutaneous Melanoma. Journal of Investigative Dermatology, 2008, 128, 1585-1588. | 0.3 | 25 |
| 201 | Targeted Therapy for Melanoma: A Primer. Surgical Oncology Clinics of North America, 2011, 20, 165-180. | 0.6 | 25 |
| 202 | Sentinel lymph node biopsy for melanoma: A critical update for dermatologists after two decades of experience. Clinics in Dermatology, 2013, 31, 298-310. | 0.8 | 25 |
| 203 | Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma. Cancer, 2007, 109, 1570-1578. | 2.0 | 24 |
| 204 | The longâ€term risk of upperâ€extremity lymphedema is twoâ€fold higher in breast cancer patients than in melanoma patients. Journal of Surgical Oncology, 2015, 112, 834-840. | 0.8 | 24 |
| 205 | The Expression of p-STAT3 in Stage IV Melanoma: Risk of CNS Metastasis and Survival. Oncotarget, 2012, 3, 336-344. | 0.8 | 24 |
| 206 | Lymphatic Mapping in the Molecular Era. Annals of Surgical Oncology, 2004, 11, 362-374. | 0.7 | 23 |
| 207 | Improving the quality of cancer staging. Ca-A Cancer Journal for Clinicians, 2015, 65, 261-263. | 157.7 | 23 |
| 208 | Role of Immune Response, Inflammation, and Tumor Immune Responseâ€“Related Cytokines/Chemokines in Melanoma Progression. Journal of Investigative Dermatology, 2019, 139, 2352-2358.e3. | 0.3 | 23 |
| 209 | Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. Journal of Clinical Oncology, 2020, 38, 1429-1441. | 0.8 | 23 |
| 210 | Association of the diversity and composition of the gut microbiome with responses and survival (PFS) in metastatic melanoma (MM) patients (pts) on anti-PD-1 therapy.. Journal of Clinical Oncology, 2017, 35, 3008-3008. | 0.8 | 23 |
| 211 | Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy. Surgery, 2017, 161, 1246-1254. | 1.0 | 22 |
| 212 | Adjuvant highâ€dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. Cancer, 2008, 112, 2030-2037. | 2.0 | 21 |
| 213 | Sentinel Lymph Node Biopsy for Melanoma: Critical Assessment at its Twentieth Anniversary. Surgical Oncology Clinics of North America, 2011, 20, 57-78. | 0.6 | 21 |
| 214 | Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Annals of Surgical Oncology, 2022, 29, 3694-3708. | 0.7 | 21 |
| 215 | Somatic Mutations in MAP3K5 Attenuate Its Proapoptotic Function in Melanoma through Increased Binding to Thioredoxin. Journal of Investigative Dermatology, 2014, 134, 452-460. | 0.3 | 20 |
| 216 | Correlates of Sun Protection and Sunburn in Children of Melanoma Survivors. American Journal of Preventive Medicine, 2016, 51, e77-e85. | 1.6 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma. Journal of the National Cancer Institute, 2020, 112, 875-885. | 3.0 | 20 |
| 218 | Biological Validation of RNA Sequencing Data From Formalin-Fixed Paraffin-Embedded Primary Melanomas. JCO Precision Oncology, 2018, 2018, 1-19. | 1.5 | 19 |
| 219 | ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Research, 2018, 78, 5680-5693. | 0.4 | 19 |
| 220 | Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. Modern Pathology, 2020, 33, 496-513. | 2.9 | 19 |
| 221 | Surgical decision-making and prioritization for cancer patients at the onset of the COVID-19 pandemic: A multidisciplinary approach. Surgical Oncology, 2020, 34, 182-185. | 0.8 | 19 |
| 222 | Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. Annals of Oncology, 2020, 31, 1569-1579. | 0.6 | 18 |
| 223 | Clinical relevance of melanoma micrometastases in sentinel nodes: too early to tell. Annals of Oncology, 2007, 18, 806-808. | 0.6 | 17 |
| 224 | Correlation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma. Clinical Cancer Research, 2019, 25, 7585-7593. | 3.2 | 17 |
| 225 | Ligand-directed targeting of lymphatic vessels uncovers mechanistic insights in melanoma metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2521-2526. | 3.3 | 16 |
| 226 | Variability in Predictions from Online Tools: A Demonstration Using Internet-Based Melanoma Predictors. Annals of Surgical Oncology, 2018, 25, 2172-2177. | 0.7 | 16 |
| 227 | Is sentinel-node biopsy superior to nodal observation in melanoma?. Nature Clinical Practice Oncology, 2007, 4, 278-279. | 4.3 | 15 |
| 228 | Impact of sentinel lymphadenectomy on survival in a murine model of melanoma. Clinical and Experimental Metastasis, 2008, 25, 191-199. | 1.7 | 15 |
| 229 | Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression. Melanoma Research, 2012, 22, 169-175. | 0.6 | 15 |
| 230 | Semiconductor-based DNA sequencing of histone modification states. Nature Communications, 2013, 4, 2672. | 5.8 | 15 |
| 231 | Impact of the 2009 (7th Edition) AJCC Melanoma Staging System in the Classification of Thin Cutaneous Melanomas. BioMed Research International, 2013, 2013, 1-7. | 0.9 | 15 |
| 232 | Functional annotation of melanoma risk loci identifies novel susceptibility genes. Carcinogenesis, 2020, 41, 452-457. | 1.3 | 15 |
| 233 | Abstract 4363: Loss of PTEN promotes resistance to T cell-mediated immunotherapy. , 2016, , . | | 15 |
| 234 | Evidence-Based Clinical Practice Guidelines on the Use of Sentinel Lymph Node Biopsy in Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e320-e325. | 1.8 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Clinical characteristics and outcomes associated with BRAF and NRAS mutations in metastatic melanoma.. Journal of Clinical Oncology, 2011, 29, 8500-8500. | 0.8 | 15 |
| 236 | An Evidence-Based Staging System for Mucosal Melanoma: A Proposal. Annals of Surgical Oncology, 2022, 29, 5221-5234. | 0.7 | 15 |
| 237 | Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma. European Journal of Cancer, 2011, 47, 107-115. | 1.3 | 13 |
| 238 | High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens. Scientific Reports, 2021, 11, 9043. | 1.6 | 13 |
| 239 | A multicentre study of naevusâ€associated melanoma vs. de novo melanoma, tumour thickness and body site differences*. British Journal of Dermatology, 2021, 185, 101-109. | 1.4 | 13 |
| 240 | Quantitative associations between health insurance and stage of melanoma at diagnosis among nonelderly adults in the United States. Cancer, 2020, 126, 775-781. | 2.0 | 12 |
| 241 | Enforcement Provisions of Indoor Tanning Bans for Minors: An Analysis of the First 6 US States. American Journal of Public Health, 2015, 105, e10-e12. | 1.5 | 11 |
| 242 | A model for predicting low probability of nonsentinel lymph node positivity in melanoma patients with a single positive sentinel lymph node. Journal of Surgical Oncology, 2018, 118, 922-927. | 0.8 | 11 |
| 243 | Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma. Clinical Cancer Research, 2018, 24, 4119-4125. | 3.2 | 11 |
| 244 | Enhancing Case Capture, Quality, and Completeness of Primary Melanoma Pathology Records via Natural Language Processing. JCO Clinical Cancer Informatics, 2019, 3, 1-11. | 1.0 | 11 |
| 245 | Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. Cancer Medicine, 2020, 9, 8650-8661. | 1.3 | 11 |
| 246 | A toll-like receptor agonist to drive melanoma regression as a vaccination adjuvant or by direct tumor application.. Journal of Clinical Oncology, 2017, 35, 9582-9582. | 0.8 | 11 |
| 247 | CDC Grand Rounds: Prevention and Control of Skin Cancer. Morbidity and Mortality Weekly Report, 2015, 64, 1312-1314. | 9.0 | 11 |
| 248 | The new staging system for cutaneous melanoma in the era of lymphatic mapping. Seminars in Oncology, 2004, 31, 415-425. | 0.8 | 10 |
| 249 | Assessment of Compliance With Texas Legislation Banning Indoor UV Tanning by Minors. JAMA Dermatology, 2017, 153, 228. | 2.0 | 10 |
| 250 | Discordance in Diagnosis of Melanocytic Lesions and Its Impact on Clinical Management. Archives of Pathology and Laboratory Medicine, 2021, 145, 1505-1515. | 1.2 | 10 |
| 251 | Surgical clinical trials in melanoma. Surgical Clinics of North America, 2003, 83, 385-403. | 0.5 | 9 |
| 252 | Gene Expression Profiling Of Human Cutaneous Melanoma: Are We There Yet?. Cancer Biology and Therapy, 2004, 3, 121-123. | 1.5 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Multi-modal molecular programs regulate melanoma cell state. Nature Communications, 2022, 13, . | 5.8 | 9 |
| 254 | Re: Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma, Thomas and Clark. European Journal of Surgical Oncology, 2005, 31, 323-324. | 0.5 | 8 |
| 255 | 4-Nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma. Melanoma Research, 2016, 26, 181-187. | 0.6 | 8 |
| 256 | Sex Differences in Age at Primary Melanoma Diagnosis in a Population-Based Analysis (USÂSurveillance,) Tj ETQq0 0 0 rgBT /Overlock 10 | 0.3 | 8 |
| 257 | Sentinel node biopsy for primary cutaneous melanoma. Annals of Oncology, 2021, 32, 290-292. | 0.6 | 8 |
| 258 | Be Well Communitiesâ„¢: mobilizing communities to promote wellness and stop cancer before it starts. Cancer Causes and Control, 2021, 32, 859-870. | 0.8 | 8 |
| 259 | Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker. Journal of Investigative Dermatology, 2022, 142, 2046-2049.e3. | 0.3 | 8 |
| 260 | Prognostic significance of the sentinel lymph node (SLN) in stage I or II melanoma patients. Melanoma Research, 1997, 7, S105. | 0.6 | 7 |
| 261 | Acne Vulgaris: False-Positive Finding on Integrated18F-FDG PET/CT in a Patient with Melanoma. American Journal of Roentgenology, 2006, 187, W117-W119. | 1.0 | 7 |
| 262 | Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes. Journal of Investigative Dermatology, 2015, 135, 2266-2272. | 0.3 | 7 |
| 263 | Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era. Annals of Surgical Oncology, 2021, 28, 3480-3489. | 0.7 | 7 |
| 264 | Tissue Resources for Clinical Use and Marker Studies in Melanoma. Methods in Molecular Biology, 2014, 1102, 679-695. | 0.4 | 7 |
| 265 | Evidence-Based Clinical Practice Guidelines on the Use of Sentinel Lymph Node Biopsy in Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e320-e325. | 1.8 | 7 |
| 266 | Identification of MicroRNAâ€“mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. Cancers, 2021, 13, 5301. | 1.7 | 7 |
| 267 | Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf -mutated melanoma. OncoImmunology, 2021, 10, 1992880. | 2.1 | 7 |
| 268 | Classification and staging of melanoma. Clinics in Laboratory Medicine, 2000, 20, 785-815. | 0.7 | 7 |
| 269 | Variants in melanocortin 1 receptor gene contribute to risk of melanoma â€“ a direct sequencing analysis in a <scp>T</scp>exas population. Pigment Cell and Melanoma Research, 2013, 26, 422-425. | 1.5 | 6 |
| 270 | Embracing changes to the American Joint Committee on Cancer 8th edition melanoma staging system. European Journal of Cancer, 2019, 112, 9-11. | 1.3 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | Clinical classification and staging. Clinics in Plastic Surgery, 2000, 27, 361-76, viii. | 0.7 | 6 |
| 272 | The relationship between blood <scp>IL</scp>â€12p40 level and melanoma progression. International Journal of Cancer, 2015, 136, 1874-1880. | 2.3 | 5 |
| 273 | Telementoring and smartphone-based answering systems to optimize dermatology resident dermoscopy education. Journal of the American Academy of Dermatology, 2019, 81, e27-e28. | 0.6 | 5 |
| 274 | Abstract 614: Resiquimod, a Toll-like receptor agonist promotes melanoma regression by enhancing plasmacytoid dendritic cells and T cytotoxic activity as a vaccination adjuvant and by direct tumor application. Cancer Research, 2018, 78, 614-614. | 0.4 | 5 |
| 275 | A phase I/II study of lymphodepletion plus adoptive cell transfer (ACT) with T cells transduced with CXCR2 and NGFR followed by high dose interleukin-2 (IL-2) in patients with metastatic melanoma (MM).. Journal of Clinical Oncology, 2016, 34, TPS9594-TPS9594. | 0.8 | 5 |
| 276 | Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage II melanoma: Phase 3 KEYNOTE-716 study.. Journal of Clinical Oncology, 2019, 37, TPS9596-TPS9596. | 0.8 | 5 |
| 277 | Outcomes After Sphincter-Sparing Local Therapy for Anorectal Melanoma: 1989 to 2020. Practical Radiation Oncology, 2022, 12, 437-445. | 1.1 | 5 |
| 278 | Management of Early-Stage Cutaneous Melanoma. Current Problems in Surgery, 2005, 42, 468-534. | 0.6 | 4 |
| 279 | CDC Grand Rounds: Prevention and Control of Skin Cancer. American Journal of Transplantation, 2016, 16, 717-720. | 2.6 | 4 |
| 280 | Melanoma Preventionâ€"Avoiding Indoor Tanning and Minimizing Overexposure to the Sun. JAMA - Journal of the American Medical Association, 2016, 316, 1913. | 3.8 | 4 |
| 281 | Staging of Cutaneous Melanoma. JAMA Network Open, 2018, 1, e180086. | 2.8 | 4 |
| 282 | Complex General Surgical Oncology Fellowship Applicants: Trends over Time and the Impact of Board Certification Eligibility. Annals of Surgical Oncology, 2019, 26, 2667-2674. | 0.7 | 4 |
| 283 | Isolated Imunohistochemistry-positive Cells Without Morphologic Characteristics of Melanoma Should Not Result in Designation as a Positive Sentinel Lymph Node According to the AJCC 8th Edition Staging System. American Journal of Surgical Pathology, 2019, 43, 1442-1444. | 2.1 | 4 |
| 284 | Abstract 2672: Response to anti-PD-1 based therapy in metastatic melanoma patients is associated with the diversity and composition of the gut microbiome. , 2017, , . | | 4 |
| 285 | Staging and prognostic factors for stage IV melanoma: Initial results of an American Joint Committee on Cancer (AJCC) international evidence-based assessment of 4,895 melanoma patients. Journal of Clinical Oncology, 2008, 26, 9035-9035. | 0.8 | 4 |
| 286 | Unraveling the prognostic heterogeneity in patients with advanced melanoma between Australia (OZ) and the United States (US): Preliminary report of the PHAMOUS study.. Journal of Clinical Oncology, 2010, 28, 8516-8516. | 0.8 | 4 |
| 287 | Adjuvant radiation therapy and chemotherapy in Merkel cell carcinoma: Survival analysis of 6,908 cases from the National Cancer Data Base.. Journal of Clinical Oncology, 2014, 32, 9014-9014. | 0.8 | 4 |
| 288 | Abstract 2972: Genomic classification of cutaneous melanoma. Cancer Research, 2015, 75, 2972-2972. | 0.4 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | Melanoma Prevention and Screening. , 2020, , 525-570. | | 4 |
| 290 | Teens and Indoor Tanning: Time to Act on the US Food and Drug Administrationâ€™s Black-Box Warning. Annals of Surgical Oncology, 2015, 22, 701-703. | 0.7 | 3 |
| 291 | The Great Debate at â€œMelanoma Bridgeâ€, Napoli, December 2nd, 2017. Journal of Translational Medicine, 2018, 16, 101. | 1.8 | 3 |
| 292 | Setting the â€œstageâ€•for Surgical Oncology fellows: Pierre Denoix and TNM staging. Journal of Surgical Oncology, 2019, 119, 823-823. | 0.8 | 3 |
| 293 | Updates in the evidenceâ€based management of cutaneous melanoma. Head and Neck, 2020, 42, 3396-3404. | 0.9 | 3 |
| 294 | Microscopic tumor burden in sentinel lymph nodes (SLNs) best predicts nonsentinel lymph node (NSLN) involvement in patients with melanoma. Journal of Clinical Oncology, 2006, 24, 8004-8004. | 0.8 | 3 |
| 295 | Molecular and immune predictors of response and toxicity to combined CTLA-4 and PD-1 blockade in metastatic melanoma (MM) patients (pts).. Journal of Clinical Oncology, 2017, 35, 9579-9579. | 0.8 | 3 |
| 296 | Relapse-free survial and target identification to enhance response with neoadjuvant and adjuvant dabrafenib + trametinib (D+T) treatment compared to standard-of-care (SOC) surgery in patients (pts) with high-risk resectable BRAF-mutant metastatic melanoma.. Journal of Clinical Oncology, 2017, 35, 9587-9587. | 0.8 | 3 |
| 297 | Abstract 1493: Therapeutic efficacy and tolerability of combined immune checkpoint blockade in metastatic melanoma patients is influenced by the gut microbiome. Cancer Research, 2019, 79, 1493-1493. | 0.4 | 3 |
| 298 | A lupus-like reaction to subcutaneous interferon-Î± at injection sites. Journal of Drugs in Dermatology, 2012, 11, 393-8. | 0.4 | 3 |
| 299 | Nodal failure after lymphatic mapping (LM) and negative sentinel lymph node (SLN) biopsy in stage I or II melanoma patients. Melanoma Research, 1997, 7, S29. | 0.6 | 2 |
| 300 | Radiation Treatment Field Delineation for Axillary Metastases from Malignant Melanoma. International Journal of Radiation Oncology Biology Physics, 2008, 72, S105-S106. | 0.4 | 2 |
| 301 | Society of surgical oncology fellowship training: Where we have been, where we are now, and where we are going. Journal of Surgical Oncology, 2009, 100, 179-181. | 0.8 | 2 |
| 302 | Have melanoma and skin cancer finally met their match?. Nature Reviews Clinical Oncology, 2017, 14, 267-268. | 12.5 | 2 |
| 303 | Melanoma Expression Genes Identified through Genome-Wide Association Study ofÂBreslow Tumor Thickness. Journal of Investigative Dermatology, 2017, 137, 253-257. | 0.3 | 2 |
| 304 | The Great Debate at â€œMelanoma Bridgeâ€, Naples, December 7th, 2019. Journal of Translational Medicine, 2020, 18, 171. | 1.8 | 2 |
| 305 | Sentinel Lymph Node Biopsy in Cutaneous Melanoma. , 2008, , 92-110. | | 2 |
| 306 | Diagnostic imaging modalities for the surveillance of melanoma patients: A meta-analysis.. Journal of Clinical Oncology, 2010, 28, 8581-8581. | 0.8 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | Melanoma Prognosis and Staging. , 2020, , 271-297. | | 2 |
| 308 | Clinically Significant Risk Thresholds in the Management of Primary Cutaneous Melanoma: A Survey of Melanoma Experts. Annals of Surgical Oncology, 2022, , . | 0.7 | 2 |
| 309 | Introduction: Lymphadenectomy for Cancer Operative Techniques in General Surgery. Operative Techniques in General Surgery, 2006, 8, 65. | 0.0 | 1 |
| 310 | Fellowship training in surgical oncology â€“ an international affair. Surgical Oncology, 2008, 17, 277-279. | 0.8 | 1 |
| 311 | Reply to J.M. Thomas et al. Journal of Clinical Oncology, 2010, 28, e480-e481. | 0.8 | 1 |
| 312 | Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall. American Journal of Dermatopathology, 2018, 40, 831-835. | 0.3 | 1 |
| 313 | Active surveillance of patients who have melanoma with a positive sentinel node in an era of effective adjuvant therapy: Early lessons learned â€¦ and still learning. Cancer, 2021, 127, 2177-2180. | 2.0 | 1 |
| 314 | The â€œGreat Debateâ€•at Melanoma Bridge 2020: December, 5th, 2020. Journal of Translational Medicine, 2021, 19, 142. | 1.8 | 1 |
| 315 | Title is missing!. , 2017, , . | | 1 |
| 316 | Abstract A32: A role for elevated leptin, independent of obesity, in the progression of melanoma. , 2015, , . | | 1 |
| 317 | Survival in patients with synchronous versus metachronous lymph node (LN) involvement in stage III melanoma: Is there a difference?. Journal of Clinical Oncology, 2008, 26, 9034-9034. | 0.8 | 1 |
| 318 | Correlation of prevalence of CD68+ macrophages within tumor-draining lymph node basins and overall survival in stage III melanoma patients.. Journal of Clinical Oncology, 2010, 28, e21034-e21034. | 0.8 | 1 |
| 319 | Impact of comorbidities on overall survival of high-risk and advanced melanoma.. Journal of Clinical Oncology, 2012, 30, 8536-8536. | 0.8 | 1 |
| 320 | Lymphodepletion (LD), tumor-infiltrating lymphocytes (TIL) and high (HD-IL2) versus low-dose (LD-IL2) IL-2 followed by pembrolizumab (pembro) in patients (pts) with metastatic melanoma (MM).. Journal of Clinical Oncology, 2019, 37, 9543-9543. | 0.8 | 1 |
| 321 | Significance of Plasma Cytokine Levels in Melanoma Patients With Histologically Negative Sentinel Lymph Nodes. , 2001, 8, 116. | | 1 |
| 322 | Prognostic value of S100B levels and LDH levels in melanoma patients. Journal of Clinical Oncology, 2008, 26, 9002-9002. | 0.8 | 1 |
| 323 | Abstract 968: Molecular and clinical correlates of PTEN expression in melanoma. , 2012, , . | | 1 |
| 324 | Abstract LB-315: Comprehensive genomic characterization of cutaneous melanoma. , 2014, , . | | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 325 | Abstract CT156: Novel neoadjuvant targeted therapy trial yields insight into molecular mechanisms of response. Cancer Research, 2017, 77, CT156-CT156. | 0.4 | 1 |
| 326 | Melanoma Prevention and Screening. , 2019, , 1-46. | | 1 |
| 327 | Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma.. Journal of Clinical Oncology, 2019, 37, TPS145-TPS145. | 0.8 | 1 |
| 328 | Utilization and evolving prescribing practice of opioid and nonâ€opioid analgesics in patients undergoing lymphadenectomy for cutaneous malignancy. Journal of Surgical Oncology, 2022, 125, 719-729. | 0.8 | 1 |
| 329 | Preface. Surgical Oncology Clinics of North America, 2011, 20, xv-xvi. | 0.6 | 0 |
| 330 | Lymphatic Mapping and Sentinel Lymph Node Biopsy. , 0, , 501-515. | | 0 |
| 331 | Staging and Classification of Melanoma. , 2018, , 87-103. | | 0 |
| 332 | Melanoma Clinical Staging (Historical and Current). , 2019, , 485-500. | | 0 |
| 333 | Completion Node Dissection for Sentinel Node-Positive Melanoma: Can a Systematic Review Bring One Discussion to a Close While Leaving the Broader Conversation Still Open?. Annals of Surgical Oncology, 2019, 26, 921-923. | 0.7 | 0 |
| 334 | Reliability and validity of the Functional Assessment of Cancer Therapy-melanoma (FACT-M). Journal of Clinical Oncology, 2007, 25, 8554-8554. | 0.8 | 0 |
| 335 | HLA class II alleles predict recurrence and pattern of failure in early-stage melanoma patients. Journal of Clinical Oncology, 2007, 25, 8503-8503. | 0.8 | 0 |
| 336 | Abstract 5568: Elevated interleukin-12 is a plasma marker of poor prognosis in stage III melanoma patients. , 2008, , . | | 0 |
| 337 | Therapeutic Targeting of the Lymphovascular System in Cancer: Promise and Challenge. , 2009, , 191-199. | | 0 |
| 338 | Effect of clinical status and previous treatment of melanoma patients on expansion of TIL for adoptive T-cell therapy. Journal of Clinical Oncology, 2009, 27, 3021-3021. | 0.8 | 0 |
| 339 | Quantitative assessment of AKT activation in melanoma. Journal of Clinical Oncology, 2009, 27, 9022-9022. | 0.8 | 0 |
| 340 | Patterns of recurrence in 208 patients with Merkel cell carcinoma.. Journal of Clinical Oncology, 2010, 28, 8556-8556. | 0.8 | 0 |
| 341 | The impact of physician specialty on quality of melanoma care.. Journal of Clinical Oncology, 2010, 28, 8563-8563. | 0.8 | 0 |
| 342 | Prognostic Factors and Staging in Melanoma. , 2011, , 282-294. | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 343 | Abstract 4970: Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma. , 2011, , . | | 0 |
| 344 | Cutaneous Desmoplastic Melanoma. , 2014, , 1-3. | | 0 |
| 345 | Do patient-reported quality-of-life responses in melanoma patients vary by stage?. Journal of Clinical Oncology, 2014, 32, e20007-e20007. | 0.8 | 0 |
| 346 | Cutaneous Desmoplastic Melanoma. , 2016, , 1260-1262. | | 0 |
| 347 | Pathological and clinical features of non-acral cutaneous melanoma (CM) patients (pts) with TP53 and BRAFNon-V600 (NonV600) mutations (muts).. Journal of Clinical Oncology, 2016, 34, 9535-9535. | 0.8 | 0 |
| 348 | Melanoma Clinical Staging (Historical and Current). , 2018, , 1-16. | | 0 |
| 349 | Stage at presentation to determine associations between histologic parameters of primary tumor and disease specific survival (DSS) in anorectal melanoma (AM).. Journal of Clinical Oncology, 2018, 36, e21622-e21622. | 0.8 | 0 |
| 350 | Models for Predicting Melanoma Outcome. , 2019, , 1-16. | | 0 |
| 351 | Melanoma Prognosis and Staging. , 2019, , 1-27. | | 0 |
| 352 | Abstract 499: NanoStringÂ®GeoMxÂ®digital spatial profiling further defines the role of B cells in the response to immune checkpoint blockade. , 2019, , . | | 0 |
| 353 | Abstract 4488: Effector B cells and tertiary lymphoid structures predict response to immune checkpoint blockade in solid tumors. , 2019, , . | | 0 |
| 354 | Abstract 1344: IL-6 blood level represents an independent biomarker of melanoma patient prognosis. , 2019, , . | | 0 |
| 355 | Models for Predicting Melanoma Outcome. , 2020, , 299-314. | | 0 |
| 356 | Abstract P3-08-38: Primary cutaneous melanoma of the breast in women. A retrospective study of 82 patients. , 2020, , . | | 0 |
| 357 | The â€œGreat Debateâ€•at Melanoma Bridge 2021, December 2ndâ€“4th, 2021. Journal of Translational Medicine, 2022, 20, 200. | 1.8 | 0 |
| 358 | ASO Visual Abstract: An Evidence-Based Staging System for Mucosal Melanoma: a Proposal. Annals of Surgical Oncology, 2022, , . | 0.7 | 0 |